항혈소판약 시장 : 약제 클래스별, 투여 경로별, 유통 채널별 - 세계 기회 분석과 산업 예측(2023-2032년)

Antiplatelet Market By Drug Class (Adenosine diphosphate receptor inhibitors, Irreversible inhibitors cyclooxygenase, Others), By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 7,952,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,322,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

Allied Market Research가 발행한 조사 리포트 '항혈소판 시장'에 따르면 항혈소판 시장은 2022년에 38억 달러로 평가되며, 2023-2032년 CAGR 4.2%로 성장하며, 2032년에는 58억 달러에 달할 것으로 추정되고 있습니다.

혈소판은 부상 후 출혈을 멈추는 과정인 지혈에 중요한 역할을 합니다. 혈관이 손상되면 혈소판이 그 부위에 달라붙어 응집하여 혈전을 형성하여 상처를 막는다. 그러나 죽상 동맥 경화증이나 부정맥과 같은 특정 질병 상태에서는 혈전이 혈관에 부적절하게 형성되어 심장 마비나 뇌졸중을 유발하는 막힘을 유발할 수 있습니다. 항혈소판약는 혈소판 활성화와 응집 과정의 여러 단계를 억제하여 작용합니다. 일반적으로 사용되는 항혈소판약에는 아스피린, 클로피도그렐, 티카그렐롤, 플라스그렐 등이 있습니다. 이들 약물은 응고 경로에 관여하는 특정 수용체와 효소를 억제하여 혈소판 활성화를 억제합니다.

항혈소판약 시장은 심장마비, 뇌졸중 등 심혈관계 질환의 유병률 증가 등의 요인으로 인해 예방 및 치료 수단으로 항혈소판약에 대한 수요가 증가하면서 시장 성장을 가속하고 있습니다. 예를 들어 미국 협회에 따르면 2020년 뇌졸중 유병률은 세계에서 8,910만 명에 달했습니다. 허혈성 뇌졸중은 6,820만 명, 뇌출혈은 1,890만 명, 지주막하 출혈은 810만 명입니다. 이처럼 심혈관 질환 증가는 항혈소판약에 대한 수요를 증가시켜 시장 성장을 가속할 것입니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
    • 심혈관질환의 유병률 상승
    • 연구개발 활동의 증가
    • 노인 인구의 증가
  • 억제요인
    • 항혈소판약의 부작용
  • 기회
    • 신흥 시장에서 성장 기회
• COVID-19 시장에 대한 영향 분석

제4장 항혈소판약 시장 : 약제 클래스별

• 개요
• 아데노신2 인산(ADP) 수용체 저해제
• 비가역적 시클로옥시게나아제 저해제
• 기타

제5장 항IPLATELET 시장 : 투여 경로별

• 개요
• 경구제
• 주사제

제6장 안치프라테렛트 시장 : 유통경로별

• 개요
• 병원 약국
• 드러그스토어 및 소매 약국
• 온라인 프로바이더

제7장 안티 플라스틱 시장 안치프라테레이트 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카·중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타

제8장 경쟁 상황

• 서론
• 주요 성공 전략
• 주요 10 기업의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• AstraZeneca plc
• Bayer AG
• Eli Lilly and Company.
• Otsuka Pharmaceutical Co., Ltd.
• Sanofi S.A.
• Glenmark Pharmaceuticals Limited
• Cipla Ltd.
• Lupin
• Daiichi Sankyo Company Limited
• Chiesi Farmaceutici S.p.A.

KSA

영문 목차

영문목차

According to a new report published by Allied Market Research, titled, "Antiplatelet Market," The antiplatelet market was valued at $3.8 billion in 2022, and is estimated to reach $5.8 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032.

Platelets play a crucial role in hemostasis, the process that stops bleeding after an injury. When a blood vessel is damaged, platelets adhere to the site and aggregate together, forming a clot that helps seal the injury. However, in certain medical conditions, such as atherosclerosis or irregular heart rhythms, blood clots can form within blood vessels inappropriately, leading to blockages that may result in heart attacks or strokes. Antiplatelet drugs work by interfering with different steps in the platelet activation and aggregation process. Some commonly used antiplatelet medications include aspirin, clopidogrel, ticagrelor, and prasugrel. These drugs inhibit platelet activation by blocking specific receptors or enzymes involved in the clotting pathway.

The antiplatelets market is driven by factors such as the increase in prevalence of cardiovascular diseases, such as heart attacks and stroke that drives the demand for antiplatelet drugs as a preventive and treatment measure thereby propelling the market growth. For instance, according to the American Association, the prevalence of stroke in 2020 was 89.1 million people across the globe. In addition, the ischemic stroke was 68.2 million, that of intracerebral hemorrhage was 18.9 million, and that of subarachnoid hemorrhage was 8.1 million across the globe. Thus, rise in the cases of cardiovascular diseases drives the demand for antiplatelet drugs and propels the market growth.

In addition, ongoing R&D efforts in the field of antiplatelet drugs lead to the discovery of novel agents with enhanced efficacy and safety profiles. The introduction of new and improved drugs stimulates market growth and attracts investment in the sector. For instance, Lee's Pharmaceutical Limited is conducting a phase 1 clinical trial to investigate the tolerability, safety, and pharmacokinetics of Anfibatate.

Furthermore, percutaneous coronary intervention (PCI), commonly known as angioplasty, is a surgical procedure used to treat coronary artery disease. Antiplatelet medications play a crucial role in PCI procedures, both during and after the intervention. Thus, the surge in usage of antiplatelet drugs in percutaneous coronary intervention contributes to the expansion of the antiplatelet market.

The antiplatelet market is segmented into drug class, route of administration, distribution channel, and region. As per drug class, the market is segregated into adenosine diphosphate (ADP) receptor inhibitors, irreversible inhibitors cyclooxygenase, and others. By route of administration, it is categorized into oral and injectable. Depending on distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the antiplatelet market are AstraZeneca plc, Bayer AG, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Cipla Ltd., Otsuka Pharmaceutical Co., Ltd., Lupin, Sanofi S.A., Daiichi Sankyo Company Limited, and Chiesi Farmaceutici S.p.A. Key players operating in the market have adopted product approval as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antiplatelet market analysis from 2022 to 2032 to identify the prevailing antiplatelet market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the antiplatelet market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global antiplatelet market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

• New Product Development/ Product Matrix of Key Players
• Patient/epidemiology data at country, region, global level
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By Drug Class

• Adenosine diphosphate (ADP) receptor inhibitors
• Irreversible inhibitors cyclooxygenase
• Others

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital pharmacies
• Drug store and retail pharmacies
• Online providers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Sanofi S.A.
• Glenmark Pharmaceuticals Limited
• Cipla Ltd.
• Lupin
• Bayer AG
• Otsuka Pharmaceutical Co., Ltd.
• Daiichi Sankyo Company Limited
• Chiesi Farmaceutici S.p.A.
• AstraZeneca plc
• Eli Lilly and Company.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. High bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Rise in prevalence of cardiovascular diseases
    • 3.4.1.2. Rise in R&D activities
    • 3.4.1.3. Rise in geriatric population

• 3.4.2. Restraints
  • 3.4.2.1. Side effects of antiplatelets

• 3.4.3. Opportunities
  • 3.4.3.1. Growth opportunities in emerging markets

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: ANTIPLATELET MARKET, BY DRUG CLASS

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Adenosine diphosphate (ADP) receptor inhibitors
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Irreversible inhibitors cyclooxygenase
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Others
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: ANTIPLATELET MARKET, BY ROUTE OF ADMINISTRATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Oral
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Injectable
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country

CHAPTER 6: ANTIPLATELET MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital pharmacies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Drug store and retail pharmacies
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Online providers
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: ANTIPLATELET MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key trends and opportunities
  • 7.2.2. Market size and forecast, by Drug Class
  • 7.2.3. Market size and forecast, by Route of Administration
  • 7.2.4. Market size and forecast, by Distribution Channel
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Key market trends, growth factors and opportunities
    • 7.2.5.1.2. Market size and forecast, by Drug Class
    • 7.2.5.1.3. Market size and forecast, by Route of Administration
    • 7.2.5.1.4. Market size and forecast, by Distribution Channel
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Key market trends, growth factors and opportunities
    • 7.2.5.2.2. Market size and forecast, by Drug Class
    • 7.2.5.2.3. Market size and forecast, by Route of Administration
    • 7.2.5.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Key market trends, growth factors and opportunities
    • 7.2.5.3.2. Market size and forecast, by Drug Class
    • 7.2.5.3.3. Market size and forecast, by Route of Administration
    • 7.2.5.3.4. Market size and forecast, by Distribution Channel
• 7.3. Europe
  • 7.3.1. Key trends and opportunities
  • 7.3.2. Market size and forecast, by Drug Class
  • 7.3.3. Market size and forecast, by Route of Administration
  • 7.3.4. Market size and forecast, by Distribution Channel
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Key market trends, growth factors and opportunities
    • 7.3.5.1.2. Market size and forecast, by Drug Class
    • 7.3.5.1.3. Market size and forecast, by Route of Administration
    • 7.3.5.1.4. Market size and forecast, by Distribution Channel
    • 7.3.5.2. France
    • 7.3.5.2.1. Key market trends, growth factors and opportunities
    • 7.3.5.2.2. Market size and forecast, by Drug Class
    • 7.3.5.2.3. Market size and forecast, by Route of Administration
    • 7.3.5.2.4. Market size and forecast, by Distribution Channel
    • 7.3.5.3. UK
    • 7.3.5.3.1. Key market trends, growth factors and opportunities
    • 7.3.5.3.2. Market size and forecast, by Drug Class
    • 7.3.5.3.3. Market size and forecast, by Route of Administration
    • 7.3.5.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Key market trends, growth factors and opportunities
    • 7.3.5.4.2. Market size and forecast, by Drug Class
    • 7.3.5.4.3. Market size and forecast, by Route of Administration
    • 7.3.5.4.4. Market size and forecast, by Distribution Channel
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Key market trends, growth factors and opportunities
    • 7.3.5.5.2. Market size and forecast, by Drug Class
    • 7.3.5.5.3. Market size and forecast, by Route of Administration
    • 7.3.5.5.4. Market size and forecast, by Distribution Channel
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Key market trends, growth factors and opportunities
    • 7.3.5.6.2. Market size and forecast, by Drug Class
    • 7.3.5.6.3. Market size and forecast, by Route of Administration
    • 7.3.5.6.4. Market size and forecast, by Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key trends and opportunities
  • 7.4.2. Market size and forecast, by Drug Class
  • 7.4.3. Market size and forecast, by Route of Administration
  • 7.4.4. Market size and forecast, by Distribution Channel
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Key market trends, growth factors and opportunities
    • 7.4.5.1.2. Market size and forecast, by Drug Class
    • 7.4.5.1.3. Market size and forecast, by Route of Administration
    • 7.4.5.1.4. Market size and forecast, by Distribution Channel
    • 7.4.5.2. China
    • 7.4.5.2.1. Key market trends, growth factors and opportunities
    • 7.4.5.2.2. Market size and forecast, by Drug Class
    • 7.4.5.2.3. Market size and forecast, by Route of Administration
    • 7.4.5.2.4. Market size and forecast, by Distribution Channel
    • 7.4.5.3. India
    • 7.4.5.3.1. Key market trends, growth factors and opportunities
    • 7.4.5.3.2. Market size and forecast, by Drug Class
    • 7.4.5.3.3. Market size and forecast, by Route of Administration
    • 7.4.5.3.4. Market size and forecast, by Distribution Channel
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Key market trends, growth factors and opportunities
    • 7.4.5.4.2. Market size and forecast, by Drug Class
    • 7.4.5.4.3. Market size and forecast, by Route of Administration
    • 7.4.5.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Key market trends, growth factors and opportunities
    • 7.4.5.5.2. Market size and forecast, by Drug Class
    • 7.4.5.5.3. Market size and forecast, by Route of Administration
    • 7.4.5.5.4. Market size and forecast, by Distribution Channel
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Key market trends, growth factors and opportunities
    • 7.4.5.6.2. Market size and forecast, by Drug Class
    • 7.4.5.6.3. Market size and forecast, by Route of Administration
    • 7.4.5.6.4. Market size and forecast, by Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key trends and opportunities
  • 7.5.2. Market size and forecast, by Drug Class
  • 7.5.3. Market size and forecast, by Route of Administration
  • 7.5.4. Market size and forecast, by Distribution Channel
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Key market trends, growth factors and opportunities
    • 7.5.5.1.2. Market size and forecast, by Drug Class
    • 7.5.5.1.3. Market size and forecast, by Route of Administration
    • 7.5.5.1.4. Market size and forecast, by Distribution Channel
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Key market trends, growth factors and opportunities
    • 7.5.5.2.2. Market size and forecast, by Drug Class
    • 7.5.5.2.3. Market size and forecast, by Route of Administration
    • 7.5.5.2.4. Market size and forecast, by Distribution Channel
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Key market trends, growth factors and opportunities
    • 7.5.5.3.2. Market size and forecast, by Drug Class
    • 7.5.5.3.3. Market size and forecast, by Route of Administration
    • 7.5.5.3.4. Market size and forecast, by Distribution Channel
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Key market trends, growth factors and opportunities
    • 7.5.5.4.2. Market size and forecast, by Drug Class
    • 7.5.5.4.3. Market size and forecast, by Route of Administration
    • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. AstraZeneca plc
  • 9.1.1. Company overview
  • 9.1.2. Key Executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Bayer AG
  • 9.2.1. Company overview
  • 9.2.2. Key Executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
• 9.3. Eli Lilly and Company.
  • 9.3.1. Company overview
  • 9.3.2. Key Executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
• 9.4. Otsuka Pharmaceutical Co., Ltd.
  • 9.4.1. Company overview
  • 9.4.2. Key Executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
• 9.5. Sanofi S.A.
  • 9.5.1. Company overview
  • 9.5.2. Key Executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
• 9.6. Glenmark Pharmaceuticals Limited
  • 9.6.1. Company overview
  • 9.6.2. Key Executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
• 9.7. Cipla Ltd.
  • 9.7.1. Company overview
  • 9.7.2. Key Executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
• 9.8. Lupin
  • 9.8.1. Company overview
  • 9.8.2. Key Executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
• 9.9. Daiichi Sankyo Company Limited
  • 9.9.1. Company overview
  • 9.9.2. Key Executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
• 9.10. Chiesi Farmaceutici S.p.A.
  • 9.10.1. Company overview
  • 9.10.2. Key Executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance

관련자료